Status:
In progress
Technology type:
Medicine
Decision:
Selected
Reason for decision:
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Rationale:
Topic in appraisal
Process:
STA Standard
ID number:
6439

Provisional Schedule

Committee meeting: 2:
14 January 2026
Expected publication:
01 April 2026

Project Team

Project lead
Jeremy Powell

Email enquiries

If you have any queries please email TAteam2@nice.org.uk


External Assessment Group:
School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors
Astra Zeneca
Others
Department of Health and Social Care
 
NHS England
Patient carer groups
National Kidney Federation
Professional groups
British Cardiovascular Society
 
Royal College of Physicians
 
UK Kidney Association
Associated public health groups
Public Health Wales
 
UK Health Security Agency
Comparator companies
none
General commentators
All Wales Therapeutics and Toxicology Centre
 
British National Formulary
 
Department of Health - Northern Ireland
 
Healthcare Improvement Scotland
 
Medicines and Healthcare products Regulatory Agency
 
Welsh Government
 
Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
05 November 2025 - 26 November 2025 Draft guidance
08 October 2025 Committee meeting
08 October 2025 Declaration of interests
11 April 2025 Due to an unforeseen change in External Assessment Group (EAG) availability, the timelines for this appraisal have been revised. The first committee meeting will now be held on 8 October 2025.
25 October 2024 Invitation to participate
25 October 2024 In progress. Final scope issued.
28 August 2024 - 11 September 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
31 May 2024 Awaiting development

For further information on our processes and methods, please see our CHTE processes and methods manual